1 results match your criteria: "Beijing.Lingchuan Center for Disease Control and Prevention[Affiliation]"
Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
Influenza Other Respir Viruses
November 2013
Guangxi Centers for Diseases Control and Prevention, Nanning.National Institutes for Food and Drug Control, Beijing.Chinese Center for Disease Control and Prevention, Beijing.Sinovac Biotech Co. Ltd, Beijing.Lingchuan Center for Disease Control and Prevention, Guilin, China.
Objectives: The goal of this double-blind, randomized, controlled clinical trial was to assess the safety and immunogenicity of two different doses of a monovalent split-virion 2009 pandemic influenza A/H1N1 vaccine without adjuvant in Chinese infants aged 6-35 months. DESIGN AND SETTING Subjects were randomly assigned to receive either a 2009 pandemic (H1N1) vaccine containing 7.5 or 15 μg haemagglutinin (HA) or a seasonal influenza vaccine.
View Article and Find Full Text PDF